Modulation of immune responses in lentiviral vector-mediated gene transfer

Research output: Contribution to journalReview articlepeer-review


Lentiviral vectors (LV) are widely used vehicles for gene transfer and therapy in pre-clinical animal models and clinical trials with promising safety and efficacy results. However, host immune responses against vector- and/or transgene-derived antigens remain a major obstacle to the success and broad applicability of gene therapy. Here we review the innate and adaptive immunological barriers to successful gene therapy, both in the context of ex vivo and in vivo LV gene therapy, mostly concerning systemic LV delivery and discuss possible means to overcome them, including vector design and production and immune modulatory strategies.

Original languageEnglish
Article number103802
JournalCellular Immunology
Publication statusPublished - Aug 2019


  • Gene therapy
  • Immune responses in gene therapy
  • Immune-modulation strategies in gene therapy
  • Transgene-specific immune tolerance

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'Modulation of immune responses in lentiviral vector-mediated gene transfer'. Together they form a unique fingerprint.

Cite this